Navigation Links
Generex Announces $3.0 Million Capital Investment
Date:1/25/2011

per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance.  In addition, with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each warrant will be increased or decreased proportionately, so that after such adjustment the aggregate warrant exercise price payable for the adjusted number of shares issuable upon exercise will be the same as the aggregate warrant exercise price in effect immediately prior to such adjustment.

Generex intends to use the net proceeds from the offering for general corporate purposes which will include, inter alia, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications, and general working capital.

The closing of the offering is expected to take place on or about January 25, 2011, subject to the satisfaction of customary closing conditions.

Seahawk Capital Partners, Inc. was paid a finders' fee by the Company in connection with this offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  Generex is offering these securities pursuant to an effective shelf registration statement and only by prospectus.  Copies of the final prospectus supplement in respect of the offering, together with the accompanying base prospectus, can be obtained at the Securities and Exchange Commission's website at http://www.sec.gov.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Additional Details for October 21st Live Video Webcast
2. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
3. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
4. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
5. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
6. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
7. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
10. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
11. Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... ... A new host-based therapy for Ebola, anthrax and other ... and its collaborators. The discovery has the potential to speed to market treatments ... by Scientific Reports, an open access research journal from the publishers of Nature. ...
(Date:8/31/2015)... GUELPH, ON , Aug. 31, 2015 /PRNewswire/ - BIOREM ... new orders totalling $5.7 million. The orders are for air emission ... "Of particular note is a large order for a ... our equipment will be replacing a competitor,s system that failed ... see in our engineered solutions," said Derek S. Webb ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Israel Biomedical Sensors market is estimated at $0.19 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... Aug. 31, 2015  US-Australian drug discovery company, ... today confirmed its comprehensive scientific review has identified ... in areas of unmet patient need. Novogen is ... preclinical projects prior to entering into Phase 1 ... Acting Chief Executive Officer, Iain Ross ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced preliminary ... 30, 2007 and updated its financial,outlook for ... in conjunction with the,release of Boston Scientific ...
... 19 An affiliate of,Phlo Corporation (Pink ... distribution of its vitality product, AQUISS(TM), in ... within Northern California and has,been introduced into ... Springs area. In Northern California, AQUISS(TM) ...
... Radi Medical Systems Sponsors Case Review with Drs. Morton Kern, Nico ... ... Oct. 19 The use,of fractional flow reserve (FFR) for optimizing ... Cardiovascular,Therapeutics symposium, TCT 2007, which will take place Oct. 20-25 in,Washington. ...
Cached Biology Technology:Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 3Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 5Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 6Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 7Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 8Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 9Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 10Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 11AQUISS Continues Expansion Into New Territory 2Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 2
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... cycle of ancient flatworms that cause schistosomiasis, Case Western ... to development of the parasites within humans a ... the activator, which turns on rapid growth, is in ... Schistosomiasis, which causes organ damage and failure, ...
... Fla. -- Invasive Burmese python hatchlings from the Florida ... to potentially expand their range through ocean and estuarine ... the Journal of Experimental Marine Biology and Ecology ... conducted by researchers from the U.S. Geological Survey, ...
... Daily doses of a soy germ-based nutritional ... significantly reducing hot flash frequency after 12 weeks ... women published in the peer-reviewed Journal of ... that S-equol, produced from the isoflavone daidzein during ...
Cached Biology News:Crucial gene activator in slow-killing parasite identified 2Crucial gene activator in slow-killing parasite identified 3Salt water alone unlikely to halt Burmese python invasion 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 3New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 4New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 5
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
... The iCycler thermal cycler with 96 x ... nucleic acid amplification (PCR) applications. It is ... (15-100 microliter samples) that is compatible with ... temperature monitoring and control by algorithm, block, ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Biology Products: